AR and prostate carcinoma: Because of the crucial role of AR in the development and progression of prostate cancer, androgen deprivation therapy (ADT) is the standard-of-care therapy for relapsed or metastatic patients attained by either surgery or medical castration with luteinizing hormone-releasing hormone (LHRH) agonists or antagonists[3].